Publicaciones en colaboración con investigadores/as de Thomas Jefferson University (2)

2016

  1. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): An open-label, randomised, phase 3 trial

    The Lancet Oncology, Vol. 17, Núm. 3, pp. 357-366

2014

  1. Survival of women with inflammatory breast cancer: A large population-based study

    Annals of Oncology, Vol. 25, Núm. 6, pp. 1143-1151